Angela Rossetti Net Worth

The estimated Net Worth of Angela Rossetti is at least $201 mil dollars as of 9 June 2016. Ms. Rossetti owns over 20,000 units of Palatin Technologies stock worth over $201,094 and over the last 10 years she sold PTN stock worth over $0. In addition, she makes $0 as Independent Director at Palatin Technologies.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Rossetti PTN stock SEC Form 4 insiders trading

Angela has made over 3 trades of the Palatin Technologies stock since 2015, according to the Form 4 filled with the SEC. Most recently she exercised 20,000 units of PTN stock worth $28,600 on 9 June 2016.

The largest trade she's ever made was exercising 20,000 units of Palatin Technologies stock on 9 June 2016 worth over $28,600. On average, Angela trades about 3,571 units every 25 days since 2014. As of 9 June 2016 she still owns at least 140,625 units of Palatin Technologies stock.

You can see the complete history of Ms. Rossetti stock trades at the bottom of the page.

Angela Rossetti biography

Angela Rossetti serves as Independent Director of the Company. She has been a director of Palatin since June 2013. Ms. Rossetti consults with pharmaceutical companies, including consultation on rare disease indications and utilization in low- and middle-income markets. From June 2015 through July 2017, she served as Executive Vice President of Cell Machines, Inc., an early stage biopharmaceutical company developing novel protein therapies. Previously, Ms. Rossetti served in pharmaceutical marketing, communications and financial roles, including as Vice President at Pfizer Inc., where she led a global commercial medicine team for smoking cessation, and as an Assistant Vice President at Wyeth, managing a global hemophilia business. Previously, she was President of Ogilvy Healthworld, an advertising business in the pharmaceutical and biotechnology sectors, and served on the Biotech and Pharmaceutical Advisory Board of Danske Capital for six years. Ms. Rossetti graduated from a joint program of the Albert Einstein College of Medicine and Benjamin N. Cardozo School of Law with an M.S.in Bioethics in 2014, has an M.B.A. in Finance from Columbia University Graduate School of Business and a B.A. in Biology from the University of Pennsylvania, and is an adjunct Assistant Professor at New York Medical College.

How old is Angela Rossetti?

Angela Rossetti is 67, she's been the Independent Director of Palatin Technologies since 2013. There are 2 older and 8 younger executives at Palatin Technologies. The oldest executive at Palatin Technologies Inc. is Robert deVeer, 74, who is the Independent Director.

What's Angela Rossetti's mailing address?

Angela's mailing address filed with the SEC is C/O AETHLON MEDICAL, INC., 11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO, CA, 92121.

Insiders trading at Palatin Technologies

Over the last 22 years, insiders at Palatin Technologies have traded over $3,929,269 worth of Palatin Technologies stock and bought 390,692 units worth $374,235 . The most active insiders traders include Austin W & Greenhouse David..., Partners L P/Ilbiotechnolog... y Carl Spana. On average, Palatin Technologies executives and independent directors trade stock every 76 days with the average trade being worth of $128,497. The most recent stock trade was executed by Stephen T Wills on 1 August 2024, trading 4,999 units of PTN stock currently worth $8,298.

What does Palatin Technologies do?

palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy

Complete history of Ms. Rossetti stock trades at Aethlon Medical Inc y Palatin Technologies

Palatin Technologies executives and stock owners

Palatin Technologies executives and other stock owners filed with the SEC include:

• Carl Spana,
  President, Chief Executive Officer, Director
• stephen Wills,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary
• Dr. Carl Spana Ph.D.,
  Co-Founder, Pres, CEO & Director
• Stephen T. Wills CPA, CPA, MST,
  CFO, COO, Exec. VP, Treasurer & Sec.
• Angela Rossetti,
  Independent Director
• Arlene Morris,
  Independent Director
• Anthony Manning,
  Independent Director
• Joseph Hull,
  Independent Director
• Alan Dunton,
  Independent Director
• Robert deVeer,
  Independent Director
• John Prendergast,
  Independent Chairman of the Board
• Robert Jordan,
  Sr. VP of Program Operations
• John Dodd Ph.D.,
  Sr. VP of Preclinical Devel.
• James E. Hattersley,
  Sr. VP of Bus. Devel.
• Dr. Michael B. Raizman M.D.,
  Chief Medical Officer
• Stephen A. Slusher Esq.,
  Chief Legal Officer
• Burns McClellan,
  VP of Investor Relations
• Zola P Horovitz,
  Director
• Robert I Taber,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Austin W & Greenhouse David...,
  10% owner
• Errol B Desouza,
  Director
• Trevor Hallam,
  Exec. VP Res. & Dev.
• Perry B Molinoff,
  Exec. VP Research and Devel.
• Investments Lpproquest Asso...,
  
• Joseph Edelman,
  10% owner